Ipolamiide Extracts for Selective CD8+ T Cell Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immunological disorders, particularly autoimmune diseases like vitiligo, lack effective medications, especially those derived from natural extracts, and existing immunosuppressive therapies are costly, non-selective, and have limitations in efficacy and accessibility.
Innovation Solution
Development of immunosuppressive compounds and extracts derived from ipolamiide, obtained through a unique production process, which inhibit CD8+ T cell activation and reduce IFN-γ secretion, providing a promising mechanism for treating immunological disorders such as vitiligo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive therapies are used, then immunosuppressive effect is achieved, but selectivity is poor and cost is high
Solution Approach 1:
The patent extracts and isolates specific immunosuppressive compounds (ipolamiide and its derivatives) from the Stachytarpheta cayennensis plant. By separating the active immunosuppressive components from the whole plant extract, the invention achieves selective immunosuppression while maintaining the therapeutic effect, directly resolving the contradiction between effectiveness and selectivity
Solution Approach 2:
The patent identifies and develops specific compounds (ipolamiide and its derivatives) with distinct immunosuppressive properties from the plant extract. By focusing on these specific compounds rather than using the whole extract or conventional broad-spectrum immunosuppressants, the invention achieves both high selectivity and reliable immunosuppressive effect
2Adaptability or versatility
If monoclonal antibodies are used for targeted therapy, then selectivity is improved, but cost and accessibility are reduced
Solution Approach 1:
The patent employs natural plant-derived compounds (ipolamiide and its derivatives) as alternatives to expensive monoclonal antibodies. These plant compounds can be produced through cultivation and extraction processes that are significantly more cost-effective than monoclonal antibody production, while maintaining selective immunosuppressive activity through the specific action on CD8+ T cells
Solution Approach 2:
The patent identifies and utilizes naturally occurring compounds (ipolamiide and derivatives) that replicate the selective immunosuppressive effect of monoclonal antibodies. By copying the therapeutic effect through naturally available plant compounds rather than expensive biologically engineered antibodies, the invention achieves both selectivity and cost-effectiveness
3Ease of manufacture
If natural products are used for treatment, then accessibility and cost are improved, but efficacy and selectivity are reduced
Solution Approach 1:
The patent extracts and isolates specific active compounds (ipolamiide and its derivatives) from the Stachytarpheta cayennensis plant. By separating and concentrating these specific immunosuppressive components, the invention maintains the accessibility and cost advantages of natural products while achieving reliable and selective immunosuppressive efficacy through standardized extraction processes
Solution Approach 2:
The patent employs standardized extraction processes with controlled parameters (temperature, solvent composition, extraction time) to optimize the yield and purity of ipolamiide and its derivatives. By controlling these parameters, the invention ensures consistent immunosuppressive activity and selectivity while maintaining the cost-effectiveness of plant-based production
Data Source
Figure 1~2B
Figure 2C~3
Figure 4
AI summary
The present invention discloses enriched extracts from plants of the genus Stachytarpheta comprising ipolamiide and compounds of the formulae (I), (II) and/or (III): Such extracts could be useful to block activation of CD8+ T cells and reduce secretion of IFNgamma. They could have immunosuppressive activity and could be useful in methods of treatment of immunological disorders and vitiligo. Preferred compounds of formulae (I), (II) and (III) are compounds of the formulae (IV) to (XI): Additionally the extracts preferably contain also compounds of the formulae (XII) to (XVI):